http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1226221-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_25f5e60cca882cd756ee1cd36c3fef16 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 |
| filingDate | 1984-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1987-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_483b8706dfe6bff8994a5b6a96ed2449 |
| publicationDate | 1987-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1226221-A |
| titleOfInvention | Triphasic oral contraceptive |
| abstract | TRIPHASIC ORAL CONTRACEPTIVE ABSTRACT A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 0.02-0.05 mg of 17.alpha.-ethinylestra-diol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 6-8 days without administering either an estrogen or a progestogen. |
| priorityDate | 1983-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.